Showing results 121 to 140 of 290
  MIP3 alpha stimulates the migration of Langerhans cells in models of human papillomavirus (HPV)-associated (pre)neoplastic epitheliumHerman, Ludivine  ; Hubert, Pascale ; Caberg, Jean-Hubert et alin Cancer Immunology, Immunotherapy (2007), 56(7), 1087-1096 Detailed reference viewed: 42 (4 ULg)Study of the relationship between lipid binding properties of cyclodextrins and their effect on the integrity of liposomesPiel, Géraldine ; Piette, Marie ; et alin International Journal of Pharmaceutics (2007), 338(1-2), 35-42 It is well known that cyclodextrins are able to extract lipids constituting membranes, increasing their fluidity and permeability. This behaviour towards biological membranes is directly linked to the ... [more ▼] It is well known that cyclodextrins are able to extract lipids constituting membranes, increasing their fluidity and permeability. This behaviour towards biological membranes is directly linked to the toxicological effects of methylated cyclodextrins. However, confusion is currently made in the literature between the different methylated cyclodextrin derivatives. Moreover, a new methylated cyclodextrin derivative recently occurred in the market. the Crysmeb (R). We wanted to compare and understand the effect of the most currently used cyclodextrins on a model membrane. We studied the influence of natural cyclodextrins (beta CD and gamma CD), methylated derivatives (2,6-dimethyl-beta CD (Dimeb), 2,3,6-trimethyl-beta CD (Trimeb) and randomly methylated-beta CD (Rameb), as well as the new derivative Crysmeb), hydroxypropylated derivatives (HP beta CD of different substitution degrees and HP gamma CD) and the sulfobutylated derivative (SBE beta CD) on the release of a fluorescent marker encapsulated in the inner cavity of liposomes. It was shown that the observed effect on calcein release can be directly related to the affinity of cyclodextrins for both lipid components of liposomes, cholesterol and phosphatidylcholine. From this relationship, we were able to determine, for each cyclodextrin, a theoretical concentration giving rise to 50% or 100% calcein release. This theoretical concentration was confirmed experimentally. We have also showed that cyclodextrins which provoke calcein release also induce large structure modifications of liposomes. (c) 2007 Elsevier B.V. All rights reserved. [less ▲] Detailed reference viewed: 36 (11 ULg)USE OF CYCLODEXTRIN FOR TREATMENT AND PREVENTION OF BRONCHIAL INFLAMMATORY DISEASES.Cataldo, Didier ; Evrard, Brigitte ; Foidart, Jean-Michel et alPatent (2007) Detailed reference viewed: 7 (3 ULg)Study of the interaction between cyclodextrins and liposome membranes: effect on the permeability of liposomesPiel, Géraldine ; Piette, Marie ; et alin Journal of Inclusion Phenomena and Macrocyclic Chemistry (2007, April), 57(1-4), 309-311 We wanted to compare and understand the effect of the most currently used cyclodextrins on a model membrane. We studied the influence of most currently used cyclodextrins on the release of a fluorescent ... [more ▼] We wanted to compare and understand the effect of the most currently used cyclodextrins on a model membrane. We studied the influence of most currently used cyclodextrins on the release of a fluorescent marker encapsulated in the inner cavity of SUV liposomes. It was shown that the observed effect on calcein release can be directly related to the affinity of cyclodextrins for both lipid components of liposomes, cholesterol and phosphatidylcholine. From this relationship, we were able to determine, for each cyclodextrin, a theoretical concentration giving rise to 50% or 100% calcein release. This theoretical concentration was confirmed experimentally. [less ▲] Detailed reference viewed: 54 (7 ULg)Contribution of cyclodextrins in the development of different pharmaceutical formulations of a new matrix metalloproteinase inhibitorEvrard, Brigitte ; ; Guéders, Maud et alin Journal of Inclusion Phenomena and Macrocyclic Chemistry (2007, April), 57(1-4), 303-308 Ro 28-2653 is a new synthetic inhibitor of matrix metalloproteinases. The ability of these enzymes to degrade various components of the extracellular matrix seems to play a major role in tumors ... [more ▼] Ro 28-2653 is a new synthetic inhibitor of matrix metalloproteinases. The ability of these enzymes to degrade various components of the extracellular matrix seems to play a major role in tumors progression and is potentially effective against bronchial remodeling in asthma and BPCO. Ro 28-2653 is very poorly soluble in water. This low solubility estimated at about 0.56 mu g/ml in water at 25 degrees C gives rise to difficulties in pharmaceutical formulation of oral, injectable or nebulizable solutions. The purpose of our study is to prepare and to characterize inclusion complexes between Ro 28-2653 and cyclodextrins and to investigate the biopharmaceutical repercussion of the inclusion of the active substance. The complex formation was investigated by phase solubility studies. H-1-NMR spectroscopy and molecular modeling studies were carried out to elucidate the structure of the inclusion complex between Ro 28-2653 and cyclodextrin. Oral, intravenous and nebulizable solutions of Ro 28-2653 were developed with cyclodextrin. The in vivo studies were performed on healthy sheep for the pharmacokinetic evaluation of the oral and intravenous formulations while the nebulization of the complex solution was studied by using an asthma model in mouse. [less ▲] Detailed reference viewed: 43 (9 ULg)Solid lipid microparticles as a sustained release system for pulmonary drug deliveryJaspart, Séverine ; ; Piel, Géraldine et alin European Journal of Pharmaceutics & Biopharmaceutics (2007), 65(1), 47-56 The controlled release of drugs for pulmonary, delivery is a research field which has been so far rather unexploited but is currently becoming increasingly attractive. The introduction part of this ... [more ▼] The controlled release of drugs for pulmonary, delivery is a research field which has been so far rather unexploited but is currently becoming increasingly attractive. The introduction part of this research article first details the potential advantages of solid lipid microparticles (SLMs) as drug carrier compared to liposomes and polymeric microspheres. The aim of this work is to use SLMs to impart a sustained release profile to a model drug, salbutamol acetonide (SA). SA was synthesized from salbutamol in order to increase the lipophilicity of this molecule and thereby to increase its incorporation efficiency into SLMs. SA-loaded SLMs were then produced by a hot emulsion technique followed by high-shear homogenisation and the manufacturing parameters were optimized using the experimental design methodology in order to reach a suitable particle size for pulmonary administration. Scanning electron micrographs showed that SLMs are spherical, have a smooth surface and that SA crystallises outside of the particles when the drug loading is higher than 20%. This was confirmed by X-ray diffraction. SA in vitro release study from SLMs showed that the release rate increased with SA loading but remained in every case lower than the dissolution rate of pure SA. (c) 2006 Elsevier B.V. All rights reserved. [less ▲] Detailed reference viewed: 80 (22 ULg)Formulation and in vitro evaluation of inhalable dry powders containing solid lipid nanoparticlesJaspart, Séverine ; Delattre, Luc ; Evrard, Brigitte Poster (2007) Detailed reference viewed: 8 (1 ULg)Supercritical fluid technology to produce solid lipid microparticles; Jaspart, Séverine ; et alConference (2007) Detailed reference viewed: 16 (3 ULg) Contribution of cyclodextrins in the developement of different pharmaceutical formulations of a nex matrix metalloproteinase inhibitorEvrard, Brigitte ; ; Guéders, Maud et alin Journal of Inclusion Phenomena and Molecular Recognition in Chemistry (2007) Ro 28-2653 is a new synthetic inhibitor of matrix metalloproteinases. The ability of these enzymes to degrade various components of the extracellular matrix seems to play a major role in tumors ... [more ▼] Ro 28-2653 is a new synthetic inhibitor of matrix metalloproteinases. The ability of these enzymes to degrade various components of the extracellular matrix seems to play a major role in tumors progression and is potentially effective against bronchial remodeling in asthma and BPCO. Ro 28-2653 is very poorly soluble in water. This low solubility estimated at about 0.56 lg/ml in water at 25 C gives rise to difficulties in pharmaceutical formulation of oral, injectable or nebulizable solutions. The purpose of our study is to prepare and to characterize inclusion complexes between Ro 28-2653 and cyclodextrins and to investigate the biopharmaceutical repercussion of the inclusion of the active substance.The complex formation was investigated by phase solubility studies. 1H-NMR spectroscopy and molecular modeling studies were carried out to elucidate the structure of the inclusion complex between Ro 28-2653 and cyclodextrin. Oral, intravenous and nebulizable solutions of Ro 28-2653 were developed with cyclodextrin. The in vivo studies were performed on healthy sheep for the pharmacokinetic evaluation of the oral and intravenous formulations while the nebulization of the complex solution was studied by using an asthma model in mouse. [less ▲] Detailed reference viewed: 22 (12 ULg)Encapsulation of betamethasone-HP-gCD complex in deformable liposomesPiel, Géraldine ; Ducat, Emilie ; Grammenos, Angeliki et alPoster (2007) Detailed reference viewed: 3 (1 ULg)DEVELOPMENT OF AN INTRAPERITONEAL IMPLANT FOR THE ENDOMETRIOSIS TREATMENTKrier, Fabrice ; ; Riva, Raphaël et alConference (2007) Detailed reference viewed: 17 (3 ULg)Controlled release of drugs from an original multi-component device; ; Collard, Laurence et alPoster (2007) Detailed reference viewed: 19 (9 ULg)Optimization of drug-cyclodextrin complexation reaction by a static supercritical carbon dioxide method; ; Piel, Géraldine et alConference (2007) Detailed reference viewed: 6 (0 ULg)Optimisation de la réaction de complexation entre une cyclodextrine et un composé pharmaceutique par utilisation du CO2 supercritque; ; Piel, Géraldine et alConference (2007) Detailed reference viewed: 16 (0 ULg)Studies on the structure of cationic liposomes/siRNA complexes by zeta potential and size measurementDehousse, Vincent ; Piel, Géraldine ; Delattre, Luc et alConference (2007) Detailed reference viewed: 19 (3 ULg)Theoretical and experimental investigations on miconazole/cyclodextrin/acid complexes: Molecular modeling studies; Dive, Georges ; et alin International Journal of Pharmaceutics (2007), 342(1-2), 152-160 The inclusion of miconazole into cyclodextrin cavity has been demonstrated by different authors. Preliminary studies have shown which fragment of the molecule is involved in the inclusion. In the present ... [more ▼] The inclusion of miconazole into cyclodextrin cavity has been demonstrated by different authors. Preliminary studies have shown which fragment of the molecule is involved in the inclusion. In the present study, AM1 approximate molecular orbital calculations have been performed on several cyclodextrins complexes ( CD, HP CD and HP CD) with miconazole and acidic compounds (maleic, fumaric and L-tartaric acids) as partners. For all the binary complexes, the inclusion of the dichlorobenzene–CH2–O-group leads to the most stable complex. For the ternary complexes, depending on their conformation and/or their structures, the acids can either stabilize or destabilize the complex. All the theoretical results were in good agreement with experimental data of miconazole inclusion yields into cyclodextrins. This work clearly demonstrates that the structure of both cyclodextrin and acid plays a key-role in the formation of inclusion complexes. [less ▲] Detailed reference viewed: 53 (21 ULg)Phase I/IIclinical trial of local GM-CSF application in patients with cervical HPV-associated low grade squamous intraepithelial lesionsHubert, Pascale ; Doyen, Jean ; et alConference (2007) Background: Quantitative and functional alterations of professional antigen-presenting cells (APC) in SIL suggest that these lesions may have a diminished capacity to capture viral antigens. Moreover, GM ... [more ▼] Background: Quantitative and functional alterations of professional antigen-presenting cells (APC) in SIL suggest that these lesions may have a diminished capacity to capture viral antigens. Moreover, GM-CSF (whose production is decreased in HPV-transformed keratinocytes) is an essential factor for the migration of APC in cervical (pre)neoplastic lesions formed in vitro and transplanted in vivo on mouse. In this study we performed a phase I/II clinical trial in order to determine whether a local application of GM-CSF on cervical low-grade squamous intraepithelial lesions (LSIL) might increase the recruitment of APC into the epithelium and indirectly the viral antigen presentation to the immune system. Methods: Fifteen patients with LSIL (10 GM-CSF and 5 placebo) were enrolled in this study. Patients received 4 GM-CSF applications (or placebo gel) and were followed during 6-7 months. APC infiltration was quantified by immunostaining with anti-CD1a mAb. Cellular immune response was evaluated by using an IFN-gamma intracellular staining on PBMC stimulated in vitro with the E7 HPV16 protein and L1 HPV16 Virus-like particles (VLP). Hybrid capture was performed to semi-quantify the viral DNA in cervical brush specimens. Results: GM-CSF applications were well tolerated in all patients. No difference in the cytological/histological and viral parameters assessed at 2 and 6 months after the last application was observed between the GM-CSF and the placebo group. An increased number of CD1a+ APC was observed in 6/10 patients treated by GM-CSF compared to 1/5 patient in the placebo group. There was an increased immune response against HPV in the GM-CSF group showed by NK and T cells producing IFN-gamma. [less ▲] Detailed reference viewed: 30 (7 ULg)Effect of cyclodextrin derivatives on bronchial epithelial cell layer permeability; ; Delattre, Luc et alPoster (2007) Detailed reference viewed: 23 (1 ULg)Controlled release of drugs from an original multi-component device; ; Collard, Laurence et alPoster (2007) Detailed reference viewed: 7 (0 ULg)Controlled release of drug from multicomponent device; ; Jérôme, Christine et alPoster (2007) Detailed reference viewed: 4 (1 ULg) |
||
